Vaxcyte, Inc.

NASDAQ:PCVX

Biotechnology

Healthcare
$58.52 +3.83%

+$1.94 today

Market cap
$9.26B
Beta
1.24
P/E (TTM)
-7.8
EPS (TTM)
-$6.78
52W Low $29.08High $65.00

Volume 1.13M

Average 1.44M

PCVX Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Vaxcyte, Inc.NASDAQ: PCVX

Net Receivables · Q2 FY2026 · quarter ended Jun 2026

Net receivables remains negative

Q2 FY2026 net receivables was $0, compared with $0 a year earlier.

Context

  • Net receivables amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
  • Net receivables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$46.56M+125.3% YoY
Year agoJun 2025
$0— since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+125.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
46.56M USD
Year-over-year change
+125.3%

Net Receivables vs competitors

How PCVX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Net receivables amounts to 0.0% of total assets for PCVX, versus a peer median of 4.5%.
PCVX Competitors
Net Receivables for PCVX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PFEPfizer Inc.Jun 2026$12.49B USD-22.4%+2.9%6.2%
GSKGSK plcJun 2026£8.03B GBP-23.9%+7.6%13.1%
MRNAModerna, Inc.Sep 2026$1.37B USD-1.9%-44.8%10.1%
IBRXImmunityBio, Inc.Sep 2026$53.6M USD+59.0%+182.5%8.8%
NVAXNovavax, Inc.Mar 2026$23.31M USD-47.6%+8.9%2.2%
VALNValneva SEMar 2026€10.14M EUR-69.7%+5.2%2.7%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$1.34M USD-90.8%+26.3%0.5%
PCVXVaxcyte, Inc.Jun 2026$0 USD——0.0%
VIRVir Biotechnology, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding PCVX) —-23.9%+7.6%4.5%

Competitors are the stored peer set for PCVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents68.99M834.66M397.45M387.88M173.96M
Short-term Investments176.99M96.72M682.78M1.36B1.39B
Net Receivables003.61M20.66M46.56M
Inventory00000
Other Current Assets005.96M20.12M2.8M
Total Current Assets256.35M942.56M1.1B1.79B1.63B
Property, Plant & Equipment (Net)35.91M31.65M110.62M270.15M491.72M
Goodwill00000
Intangible Assets00000
Long-term Investments27.12M26.55M162.68M1.39B883.13M
Tax Assets000043.25M
Other Non-current Assets4.96M5.43M38.67M65.68M508K
Total Non-current Assets67.99M63.62M311.96M1.72B1.42B
Total Assets324.34M1.01B1.41B3.51B3.05B
Account Payables6.76M9.8M14.59M48.45M70.9M
Short-term Debt00006.12M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities3.46M1.18M11.06M20.56M105.72M
Total Current Liabilities28.72M40.53M145.34M140.18M205.75M
Long-term Debt0000111.36M
Deferred Tax Liabilities000043.25M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities96K9K0100K(111.26M)
Total Non-current Liabilities11.6M12.04M22.11M65.32M154.7M
Total Liabilities40.32M52.57M167.45M205.5M360.46M
Common Stock56K82K98K128K134K
Retained Earnings(298.64M)(522.13M)(924.39M)(1.39B)(2.15B)
Accumulated OCI(241K)(361K)179K(3.87M)1.59M
Other Stockholders Equity00000
Minority Interest00000
Total Equity284.02M953.61M1.24B3.31B2.69B
Total Debt16.78M17.94M29.22M71.11M228.84M
Net Debt(52.2M)(816.72M)(368.23M)(316.77M)54.88M

Vaxcyte, Inc.

NASDAQ:PCVX

Intrinsic Alpha fair value

Locked

Current Price

$58.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.